Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Jan 14, we downgraded Thoratec Corp. (THOR - Analyst Report), a leader in mechanical circulatory assistance devices, to Neutral based on growing competition and a more challenging outlook. The company’s third quarter 2012 revenues and earnings per share beat the Zacks Consensus Estimates.

While past results have often been good, Thoratec faces growing competition from HeartWare International (HTWR - Snapshot Report). Thoratec’s monopoly in the U.S. market, in the case of the bridge-to-transplant (BTT) indication, has come to an end following FDA approval, in November 2012, for HeartWare’s Ventricular Assist System as a BTT for patients with end-stage heart failure. HeartWare has already received CE Mark approval in Europe.

Expected market share losses to HeartWare for the BTT indication will result in a slower growth profile for Thoratec. The growth rate in the Destination Therapy (DT) market where the company faces no near-term competition will therefore determine its prospects in the medium term. Overall, the market may be broad enough to accommodate several players, assuming clinical comparability.

Lack of pipeline visibility and relative lack of milestones represents a concern. Thoratec’s third-generation pump (HeartMate III) is still in the early stages of development. Its next-generation device may not be commercially available in the U.S. for the next couple of years.

The small size of the company may restrict its ability to raise resources. The absence of strategic alliances may hinder its ability to develop new products. The unified product line of the company and its lack of product diversification are related areas of concern.

While we are non-committal on Thoratec at this time, other medical device stocks worth a look are Cantel Medical Corp. and Merit Medical Systems, Inc. (MMSI - Snapshot Report). Both are Zacks Rank #1 (Strong Buy) stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%